Key takeaways:
Blujepa (gepotidacin) and Macrobid (nitrofurantoin monohydrate / macrocrystals) are prescription antibiotics that treat urinary tract infections (UTIs). Both medications are effective options overall and share common side effects.
Blujepa is a new option that may work better for antibiotic-resistant UTIs, but it’s only meant for UTIs in certain women and girls. It also has more potential interactions than Macrobid.
Macrobid is a well-established antibiotic that comes in multiple formulations. It may be used for the treatment and prevention of UTIs, and it’s widely available as a lower-cost generic.
Save on related medications
A urinary tract infection (UTI) can quickly turn your day upside down. The constant urge to pee, the burning, and the discomfort — it’s a frustrating experience that most people want relief from as soon as possible.
The good news is that most UTIs are highly treatable with antibiotics. But not all antibiotics work the same way, and some may be more effective than others, especially with rising antibiotic resistance rates.
Blujepa (gepotidacin) and Macrobid (nitrofurantoin monohydrate / macrocrystals) are two antibiotics a healthcare professional might consider prescribing you. They both treat uncomplicated UTIs, but they work differently. One may be a better fit depending on your symptoms, medical history, and past infections.
Search and compare options
Here, we’ll cover seven ways that Blujepa and Macrobid compare, including effectiveness, side effects, and product availability.
1. Blujepa and Macrobid work differently
Macrobid is a UTI antibiotic that’s been around for years. It’s a mainstay treatment that concentrates in the urine and damages proteins that bacteria need to survive. This helps stop an infection where it starts.
Blujepa works in a different way. It belongs to a new class of antibiotics called triazaacenaphthylenes. It works by blocking two key enzymes (proteins) that bacteria need to copy their DNA. Without access to these enzymes, the bacteria can’t replicate and are killed off. This is a different way of fighting UTIs compared with older antibiotics.
Because Blujepa uses a newer mechanism, it may be especially useful in treating UTIs that don’t respond well to other antibiotics. What's more, Blujepa is FDA approved to treat urinary or genital gonorrhea in certain people ages 12 years and older.
2. Blujepa may be more effective for antibiotic-resistant UTIs
Blujepa and Macrobid are both considered effective options for treating UTIs. But an increasingly common challenge in treating UTIs is antibiotic resistance.
In clinical trials, especially the EAGLE-2 and EAGLE-3 studies, Blujepa showed positive results against specific bacteria strains that didn’t respond well to other antibiotics, including some that Macrobid may not fully treat. For people who’ve had multiple UTIs or an infection that didn’t respond to treatment, Blujepa could be a helpful option.
Assessing your options: Here’s a physician-backed summary of some of the best antibiotics for treating a urinary tract infection (UTI).
Did you receive a prescription for Blujepa (gepotidacin)? Pharmacists provide tips to get the most out of your medication.
Two formulations of nitrofurantoin: Macrobid and Macrodantin are two versions of the same medication. Read on for a breakdown of how they differ.
3. More people are eligible to take Macrobid for UTIs
Blujepa was FDA approved in March 2025 to treat uncomplicated UTIs in women and girls ages 12 and older who weigh at least 88 lbs (40 kg). It’s the first new oral antibiotic to be approved for UTIs in nearly 30 years.
Macrobid is also meant only for UTIs in women and girls. But some versions of the medication can be given to infants as young as 1 month old. There’s no body-weight restriction.
What’s more, Macrobid may be prescribed for UTI prevention, especially in people who experience frequent UTIs.
Good to know: When Blujepa is prescribed to treat gonorrhea (instead of UTIs), there's no gender or sex restriction.
4. Blujepa may be taken for fewer days, while Macrobid comes in more formulations
Blujepa is usually taken as two 750 mg tablets twice a day for 5 days for UTIs. That’s a short, fixed course designed to clear an infection quickly and effectively.
Macrobid is more flexible in how it’s prescribed, and its active ingredient comes in multiple dosage forms. Here’s a summary.
Macrobid | |||
Active ingredient | Nitrofurantoin monohydrate / macrocrystals | Nitrofurantoin macrocrystals | Nitrofurantoin |
Available as a generic? | Yes | Yes | Yes |
Formulation | Capsules | Capsules | Oral suspension (liquid) |
Available doses | 100 mg | 25 mg | 25 mg/5 mL |
Frequency of use | 2 times daily | 4 times daily | 4 times daily |
Typical duration for treatment | 5 to 7 days | 5 to 7 days | 5 to 7 days |
Minimum age for use | 12 years | 1 month | 1 month |
Your prescriber will help you choose the best antibiotic based on your age, your kidney function, and the nature of your infection.
5. Blujepa and Macrobid have similar side effects overall
Blujepa and Macrobid commonly cause similar side effects, mostly related to the digestive system. Shared Blujepa side effects and Macrobid side effects include:
Nausea
Diarrhea
Headache
Dizziness
Abdominal discomfort
Taking either medication with food can help reduce stomach-related symptoms. For most people, these issues are mild and go away once the antibiotic course is finished.
That said, there are some important differences to keep in mind.
Blujepa may cause diarrhea more frequently than Macrobid. It can also lead to neurological symptoms, such as headache and dizziness, and Blujepa has some different risks. These include rare issues such as heart rhythm changes and cholinergic effects, like muscle spasms or increased saliva.
Macrobid has a longer track record and a well-understood safety profile. While it doesn’t typically cause heart side effects, it can lead to rare but serious problems, especially with long-term use or in people with kidney disease. These include lung damage, liver damage, and peripheral neuropathy (nerve damage).
6. Blujepa tends to cause more interactions than Macrobid
Blujepa and Macrobid can both interact with other medications. This is why your healthcare team should carefully review what you’re taking before prescribing either one.
That said, Macrobid generally has less interactions than Blujepa. Most of Blujepa’s interactions occur because of how it interacts with a liver enzyme (protein) that breaks it down. Some interactions are also possible because Blujepa can rarely affect your heartbeat, among other reasons.
| Blujepa interactions | Macrobid interactions | |
|---|---|---|
| Interactions that increase the risk of side effects |
|
|
| Interactions that impair effectiveness |
|
|
| Other interactions |
|
|
This list isn’t all inclusive. Your prescriber and pharmacist will look at your medication list to make sure nothing interacts with your prescription. They’ll tell you which interactions to avoid and which ones require only a dose adjustment. Make sure they’re aware of everything you’re taking — prescription medications, over-the-counter products, and dietary supplements.
7. Only Macrobid is available as a generic
Macrobid is widely available as a generic medication. This helps keep costs down and makes it more likely to be covered by insurance. If you’re paying out of pocket, the generic version is also easier to afford, especially if you use a GoodRx coupon.
Blujepa is a brand-name-only product because it’s a newer medication. This could make it trickier to access, especially if your insurance won’t cover it right away.
Frequently asked questions
Macrobid is sometimes prescribed during pregnancy, mostly in the second and third trimesters. Blujepa hasn’t been studied in pregnant women yet, so it should generally be avoided until more safety data is available.
Blujepa is approved to treat uncomplicated UTIs in women only. It’s not well studied in men with UTIs. However, Blujepa can treat gonorrhea in both men and women; there's no sex or gender restriction.
Macrobid is sometimes prescribed during pregnancy, mostly in the second and third trimesters. Blujepa hasn’t been studied in pregnant women yet, so it should generally be avoided until more safety data is available.
Blujepa is approved to treat uncomplicated UTIs in women only. It’s not well studied in men with UTIs. However, Blujepa can treat gonorrhea in both men and women; there's no sex or gender restriction.
The bottom line
Blujepa (gepotidacin) is a new prescription antibiotic for treating uncomplicated urinary tract infections (UTIs), especially when resistance is an issue. Its mechanism and fixed treatment course could offer an advantage for some people. But Macrobid (nitrofurantoin monohydrate / macrocrystals) remains a reliable go-to choice, with a long history of use and a lower price point thanks to its generic availability.
The best UTI antibiotic depends on your symptoms, your medical history, and the type of bacteria causing your infection. Your healthcare team can help you weigh the options and choose the best antibiotic for your situation.
Why trust our experts?


References
Casper Pharma. (2025). Furadantin- nitrofurantoin suspension [package insert].
GlaxoSmithKline. (2024). EAGLE-1 phase III data show potential for gepotidacin as a new oral treatment option for uncomplicated urogenital gonorrhoea (GC) amid growing resistance to existing treatments.
GlaxoSmithKline. (2025). Blujepa (gepotidacin) approved by US FDA as oral option for treatment of uncomplicated urogenital gonorrhoea (uGC).
GlaxoSmithKline. (2025). Blujepa (gepotidacin) approved by US FDA for treatment of uncomplicated urinary tract infections (uUTIs) in female adults and paediatric patients 12 years of age and older.
GlaxoSmithKline. (2025). Blujepa- gepotidacin tablet, film coated [package insert].
Nelson, Z., et al. (2024). Guidelines for the prevention, diagnosis, and management of urinary tract infections in pediatrics and adults: A WikiGuidelines group consensus statement. JAMA Network Open.
Pakala, R. S., et al. (2023). Cholinergic medications. StatPearls.
Proctor & Gamble. (2007). Drug approval package: Macrodantin nitrofurantoin, macrocrystalline capsule. U.S. Food and Drug Administration.
RemedyRepack. (2025). Macrobid- nitrofurantoin monohydrate/macrocrystalline capsule [package insert].
Reuters. (2025). GSK’s antibiotic gets FDA priority review for oral treatment of gonorrhoea.
Squadrito, F. J., et al. (2023). Nitrofurantoin. StatPearls.
Van Beusekom, M., et al. (2024). Data show rising antibiotic resistance with repeat urinary tract infections. Center for Infectious Disease Research & Policy.
Wagenlehner, F., et al. (2024). Oral gepotidacin versus nitrofurantoin in patients with uncomplicated urinary tract infection (EAGLE-2 and EAGLE-3): two randomised, controlled, double-blind, double-dummy, phase 3, non-inferiority trials. The Lancet.











